Navigation Links
BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Date:11/5/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York.

WHEN: Monday November 10th at 12:00pm (Eastern Time)

WHERE: New York Palace Hotel, New York.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
5. BioMS Medical to present at UBS Global Life Sciences Conference
6. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. BioMS Medical Announces Second Quarter 2008 Results
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. BioMS Medical to present at BMO Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... 2017 , ... One of the world’s largest World Marrow Donor Day events ... that day, the GenCure Marrow Donor Program will be signing up potential donors for ... San Antonio. , The registration tables will be staffed by employees from all the ...
(Date:9/12/2017)... ... 2017 , ... PhysIQ, a Chicago-based company that provides a ... and clinical trial support, earned DPharm Idol 2017 honors at the 7th annual ... in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital health. The company ...
(Date:9/12/2017)... , ... September 12, 2017 , ... ... extremely pleased to announce that Jeremy Nicholson, Head of the Department of Surgery ... will deliver the 2018 Wallace H. Coulter Lecture. His presentation, “Analytical Science ...
(Date:9/12/2017)... ... September 11, 2017 , ... An August 30th article on Daily ... idea that only aging and overweight patients suffer from enlarged veins (genetics are also ... cosmetic concern. , The Washington State clinic Northwest Vein & Aesthetic Center notes ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):